Preliminary evaluation of a self-complementary AAV2/8 vector for hepatic gene transfer of human apoE3 to inhibit atherosclerotic lesion development in apoE-deficient mice

Atherosclerosis

Volumn 204, Issue 1, 2009, Pages 121-126

  Osman, Eyman ^a   Evans, Vanessa ^a   Graham, Ian R ^b   Athanasopoulos, Takis ^b   McIntosh, Jenny ^c   Nathwani, Amit C ^c   Simons, J Paul ^a   Dickson, George ^b   Owen, James S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adeno associated virus serotype 8; Atherosclerosis; Cholesterol; Gene therapy; Lipoproteins; Liver specific promoter; Viral gene transfer

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; EMBRYO; FEEDING; FEMALE; GENOME; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SEROTYPE; SEX DIFFERENCE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; AORTA; APOLIPOPROTEIN E3; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL LINE, TUMOR; CHOLESTEROL; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PILOT PROJECTS; PROMOTER REGIONS, GENETIC; SEX FACTORS; TIME FACTORS; TRANSDUCTION, GENETIC;

EID: 67349236643     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.08.043     Document Type: Article

References (30)

1. Hansson G.K. Inflammation atherosclerosis, and coronary heart disease. N Engl J Med 340 (2005) 115-126
2. Miyata M., and Smith J.D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 14 (1996) 55-61
3. Riddell D.R., Graham A., and Owen J.S. Apolipoprotein E inhibits platelet aggregation through the l-arginine:nitric oxide pathway Implications for vascular disease. J Biol Chem 272 (1997) 89-95
4. Ali K., Middleton M., Pure E., and Rader D.J. Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ Res 97 (2005) 922-927
5. Stannard A.K., Riddell D.R., Sacre S.M., et al. Cell-derived apolipoprotein E (ApoE) particles inhibit vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J Biol Chem 276 (2001) 46011-46016
6. Piedrahita J.A., Zhang S.H., Hagaman J.R., et al. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 89 (1992) 4471-4475
7. Yamamoto K., Shimano H., Shimada M., et al. Overexpression of apolipoprotein E prevents development of diabetic hyperlipidemia in transgenic mice. Diabetes 44 (1995) 580-585
8. Harris J.D., Evans V., and Owen J.S. ApoE gene therapy to treat hyperlipidemia and atherosclerosis. Curr Opin Mol Ther 8 (2006) 275-287
9. Tsukamoto K., Tangirala R., Chun S.H., Pure E., and Rader D.J. Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 19 (1999) 2162-2170
10. Harris J.D., Graham I.R., Schepelmann S., et al. Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1(-), E3(-), polymerase(-)] adenovirus vector expressing human apoE. Hum Mol Genet 11 (2002) 43-58
11. Harris J.D., Schepelmann S., Athanasopoulos T., et al. Inhibition of atherosclerosis in apolipoprotein-E-deficient mice following muscle transduction with adeno-associated virus vectors encoding human apolipoprotein-E. Gene Ther 9 (2002) 21-29
12. Evans V., Foster H., Graham I., et al. Human apoE expression from mouse skeletal muscle by electrotransfer of non-viral DNA (plasmid) and pseudotyped recombinant adeno-associated virus (AAV2/7). Hum Gene Ther 19 (2008) 569-578
13. Kitajima K., Marchadier D.H., Miller G.C., Gao G.P., Wilson J.M., and Rader D.J. Complete prevention of atherosclerosis in apoE-deficient mice by hepatic human apoE gene transfer with adeno-associated virus serotypes 7 and 8. Arterioscler Thromb Vasc Biol 26 (2006) 1852-1857
14. Nakai H., Fuess S., Storm T.A., Muramatsu S., Nara Y., and Kay M.A. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 79 (2005) 214-224
15. Davidoff A.M., Gray J.T., Ng C.Y., et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2,5 and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 11 (2005) 875-888
16. McCarty D.M., Fu H., Monahan P.E., Toulson C.E., Naik P., and Samulski R.J. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10 (2003) 2112-2118
17. Thomas C.E., Storm T.A., Huang Z., and Kay M.A. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 78 (2004) 3110-3122
18. Nathwani A.C., Gray J.T., Ng C.Y., et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 107 (2006) 2653-2661
19. Natkunarajah M., Trittibach P., McIntosh J., et al. Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2/8. Gene Ther 15 (2008) 463-467
20. Maina N., Han Z., Li X., et al. Recombinant self-complementary adeno-associated virus serotype vector-mediated hematopoietic stem cell transduction and lineage-restricted, long-term transgene expression in a murine serial bone marrow transplantation model. Hum Gene Ther 19 (2008) 376-383
21. Wu Z., Sun J., Zhang T., et al. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 16 (2008) 280-289
22. Nathwani A.C., Gray J.T., McIntosh J., et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109 (2007) 1414-1421
23. Raffai R.L., Loeb S.M., and Weisgraber K.H. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol 25 (2005) 436-441
24. Jacobs F., Snoeys J., Feng Y., et al. Direct comparison of hepatocyte-specific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer. Gene Ther 15 (2008) 594-603
25. Daugherty A., and Rateri D.L. Development of experimental designs for atherosclerosis studies in mice. Methods 36 (2005) 129-138
26. Davidoff A.M., Ng C.Y., Zhou J., Spence Y., and Nathwani A.C. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 102 (2003) 480-488
27. Waxman D.J., and Celenza J.L. Sexual dimorphism of hepatic gene expression: novel biological role of KRAB zinc finger repressors revealed. Genes Dev 17 (2003) 2607-2613
28. Yamamoto K., and Sinohara H. Regulation by sex hormones of serum levels of contrapsin and alpha 1-antiprotease in the mouse. Biochim Biophys Acta 798 (1984) 231-234
29. Thorngate F.E., Rudel L.L., Walzem R.L., and Williams D.L. Low levels of extrahepatic nonmacrophage ApoE inhibit atherosclerosis without correcting hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 20 (2000) 1939-1945
30. Bellosta S., Mahley R.W., Sanan D.A., et al. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest 96 (1995) 2170-2179